Thromb Haemost 1962; 07(01): 095-105
DOI: 10.1055/s-0038-1655458
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Potency of Tissue Thromboplastic Suspensions[*]

Seymour Gollub
1   Samuel P. Mandell Laboratory of Research Surgery, Albert Einstein Medical Center, Southern Division, Philadelphia, Pennsylvania, and Sidney Hillman Medical Center, Philadelphia
,
Abramo C. Ottolenghi
1   Samuel P. Mandell Laboratory of Research Surgery, Albert Einstein Medical Center, Southern Division, Philadelphia, Pennsylvania, and Sidney Hillman Medical Center, Philadelphia
,
Lenore Lisbinsky
1   Samuel P. Mandell Laboratory of Research Surgery, Albert Einstein Medical Center, Southern Division, Philadelphia, Pennsylvania, and Sidney Hillman Medical Center, Philadelphia
,
Alex W. Uin
1   Samuel P. Mandell Laboratory of Research Surgery, Albert Einstein Medical Center, Southern Division, Philadelphia, Pennsylvania, and Sidney Hillman Medical Center, Philadelphia
1   Samuel P. Mandell Laboratory of Research Surgery, Albert Einstein Medical Center, Southern Division, Philadelphia, Pennsylvania, and Sidney Hillman Medical Center, Philadelphia
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Summary

The potency of various human brain thromboplastic suspensions was estimated by two independent test systems. It was found that potency estimation using the in vitro system (clot acceleration) did not correlate with potency estimation of an in vivo system (thrombotic-lethal). However, good correlation between lethality and thromboplastinase labile phospholipid compartment was established. These findings are briefly discussed.

* Supported in part by grants # C 4546 and # E 3701 from The National Institutes of Health.


 
  • References

  • 1 Stefanini M, Dameshek W. The Hemorrhagic Disorders. Grune and Stratton; New York, London: 1955
  • 2 Trousseau A. Clin. méd. Hôtel Dieu 1877; 3: 94 Ed. 5. J. B. Baillier et fils, (cited by Fisher)
  • 3 Osler W, McCreae T. Cancer of the Stomach. A Clinical Study 1900; 57: 284 The Blakestone Co., Philadelphia
  • 4 Welch W. H. Thrombosis in a System of Medicine. 1909; 6: 691 1st ed. Macmellan and Co., London
  • 5 James T. G. I, Matheson M. M. Thrombophlebitis in Cancer. Practioner 1935; 137: 683
  • 6 Hayward W. A Presumed Case of Acute Yellow Atrophy of the Liver. Lancet (London) 1906; 11: 651
  • 7 Sproul E. E. Carcinoma and Venous Thrombosis. Amer. J. Cancer 1938; 34: 566
  • 8 Fisher M. M, Hochberg L. A, Wilensky N. D. Recurrent Thrombophlebitis in Malignant Tumors of the Lungs. J.A.M.A 1951; 147: 1213
  • 9 Wright I. S. Wright’s Monograph on Thrombosis: The Pathogenesis and Treatment of Thrombosis. with a Clinical and Laboratory Guide to Anticoagulant Therapy Grune and Stratton; New York, London: 1952
  • 10 Mils tone J. H. Highly Active Material that Promotes Conversion of Prothrombokinase Complex. Proc. Soc. exp. Biol. (N. Y.) 1949; 72: 315
  • 11 Milstone J. H. Fractionation of Plasma Globulin for Prothrombin. Thrombokinase and accessory Thromboplastin. J. gen. Physiol 1951; 36: 67
  • 12 Milstone J. H. Protein Thrombokinase and Lipoid Thromboplastin as Distinct Factors with Complimentary Functions. Yale J. Biol. Med 1952; 25: 19
  • 13 Nolf P. Contribution de l’étude de la coagulation du sang (3e Memoire). Les facteurs primordiaux, leur origine. Arch. int. Physiol 1908; 6: 1
  • 14 Howell W. H. Theories of Blood Coagulation. Physiol. Rev 1935; 15: 435
  • 15 Chargaff E, Cohen S. Isolation and Preparation of Thromboplastic Protein from Human Organs. J. biol. Chem 1945; 161: 389
  • 16 Shinowara G. Y. Enzyme Studies on Human Blood; Isolation and Characterization of Thromboplastic Cell and Plasma Components. J. Lab. clin. Med 1951; 38: 11
  • 17 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of Antihemophilic Factor on One-Stage Clotting Tests; Presumptive Test for Hemophilia and Simple OneStage Antihemophilic Globulin Assay Procedure. J. Lab. clin. Med 1953; 41: 637
  • 18 Baer E. Henry Ford Hospital International Blood Platelet Symposium. Little Brown and Company; Boston: 1961
  • 19 Therriault D, Nichols T, Jensen H. Purification and Identification of Brain Phospholipids associated with Thromboplastic Activity. J. biol. Chem 1958; 233: 1061
  • 20 Biggs R. G, Douglas A. S. Measurement of Prothrombin in Plasma; Case of Prothrombin Deficiency. J. clin. Path 1953; 6: 15
  • 21 Seegers W. H, Schneider C. L. Nature of Blood Coagulation Mechanism. Its Relationship to Some Unsolved Problems in Obstetrics and Gynecology. Amer. J. Obstet. Gynec 1951; 61 A: 469
  • 22 Gollub S, Feldman D, Schecter D. C, Kaplan F. E, Meranze D. R. Thromboplastinase. A New Enzyme which Destroys Thromboplastin. Proc. Soc. exp. Biol. (N. Y.) 1953; 83: 858
  • 23 Gollub S. Action of Thromboplastinase on Human Blood Thromboplastin. J. appl. Physiol 1955; 7: 409
  • 24 Gollub S, Kaplan F. E, Meranze D. R. Qualitative Differences between Brain and Lung Thromboplastic Suspensions. Amer. J. Physiol 1950; 162: 293
  • 25 King E. J. Colorimetric Determination of Phosphorus. Biochem. J 1932; 26: 292
  • 26 Lowry C. H. Protein Measurement with the Folin Phenol Reagent. J. biol. Chem 1951; 193: 265
  • 27 Fitchfield Jr. J. F, Wilcoxon F. A Simplified Method of Evaluating Dose — Effect Experiments. J. Pharmacol, exp. Ther 1949; 96: 2